Ruboxistaurin

Overview

Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor ( K i =2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC 50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC 50 of 5.9 nM.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > PKC

Product Information

• Catalog No.: HY-10195
• CAS No.: 169939-94-0
• Molecular Formula: C28H28N4O3
• Molecular Weight: 468.55
• Purity: 99.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.67 mg/mL (3.56 mM); Suspended solution
• Availability: In-stock

Source

Original product source